Teva Pharmaceutical: Shares rise after FDA approves new migraine drug | Business News,The Indian Express
Teva Earns First FDA Approval for Generic Drug for Major Depressive Disorder | 2019-10-10 | FDAnews
Teva's pursuit of J&J boosted by FDA acceptance of filing for approval of long-acting schizophrenia drug | Fierce Pharma
Teva's Austedo is first 'heavy hydrogen' drug to win US FDA approval
Teva Receives FDA Approval For Parkinson's Drug Expanded Label
Teva's ProAir Digihaler FDA Approved to Monitor Asthma and COPD Treatment - Basel St 5, Petah Tikva, Israel
Teva's Israeli Plant Receives FDA Stamp of Approval for Migraine Drug Manufacturing | Ctech
FDA Approves Teva's Generic EpiPen As Stock Rises
Israel's Teva on FDA blacklist of drugmakers creating barriers to competition | The Times of Israel
Teva Finally Wins FDA Approval for Potential Huntington's Blockbuster Austedo | BioSpace
Teva Receives FDA Approval for Migraine Autoinjector | Ctech
Teva Pharmaceutical's AirDuo Digihaler gets FDA green light | MobiHealthNews
FDA Approves Teva's First and Only Digital Inhaler with Built-In Sensors - JLM-BioCity
FDA declines to approve Teva, MedinCell's schizophrenia drug candidate
Teva, Eagle Pharmaceuticals cancer therapy approved by FDA - Philadelphia Business Journal
FDA approves first deuterated drug | C&EN Global Enterprise
TEVA PHARMACEUTICAL INDUSTRIES LTD: Teva Announces FDA Approval of AirDuo® Digihaler™ (fluticasone propionate 113 mcg and salmeterol 14 mcg) Inhalation Powder | FDA Health News
Generic EpiPen by Teva Wins FDA Nod After 2 Year Delay | Fierce Pharma
Teva gets FDA approval for 1st generic nasal spray of overdose reversal drug | The Times of Israel
Teva wins FDA approval for first-ever generic Viagra - Globes
FDA declines to approve Teva-MedinCell's risperidone injection for treating schizophrenia | Seeking Alpha
FDA approves generic EpiPen developed by Montgomery County-based Teva Pharmaceuticals USA - Philadelphia Business Journal
FDA approves Teva's generic EpiPen after yearslong delay
FDA Approval Letter - Teva Pharmaceuticals
